U.S. guidelines expand potential uses of J&J TB drug

By Julie Steenhuysen CHICAGO (Reuters) – New federal guidelines expand the range of patients who might benefit from Johnson & Johnson’s Sirturo drug for the treatment of multi-drug-resistant tuberculosis (MDR-TB), the first new type of TB drug to win U.S. regulatory approval in more than 40 years. The recommendations, issued on Thursday by the U.S. …